Exciting news about a new research collaboration to discover and develop novel therapies targeting immune checkpoint proteins for the treatment of neuroendocrine tumors and other cancers. The collaboration was announced by NexImmune Inc., a clinical-stage biotechnology company, working with Rutgers University. NET expert Dr. Steven K. Libutti (pictured), Director of Rutgers Cancer Institute of New Jersey, Vice Chancellor of Cancer Programs, Rutgers Biomedical and Health Sciences, and Senior Vice President of Oncology Services, RWJBarnabas Health, will be the principal investigator. Read more: https://www.biospace.com/article/releases/neximmune-announces-research-collaboration-with-rutgers-the-state-university-of-new-jersey-related-to-neuroendocrine-tumor-targets/?s=65
